Leonard T Heffner
Overview
Explore the profile of Leonard T Heffner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buske C, Tedeschi A, Trotman J, Garcia-Sanz R, MacDonald D, Leblond V, et al.
Future Oncol
. 2023 Feb;
19(5):345-353.
PMID: 36815271
What Is This Summary About?: This article provides a short summary of 5-year results from the iNNOVATE trial. The original paper was published in the in October 2021. People with...
2.
Gupta V, Matulis S, Barwick B, Bog R, Shebelut C, Shanmugam M, et al.
Blood Cancer J
. 2022 Aug;
12(8):115.
PMID: 35927247
No abstract available.
3.
Kaushal A, Nooka A, Carr A, Pendleton K, Barwick B, Manalo J, et al.
Blood Cancer Discov
. 2021 Nov;
2(6):600-615.
PMID: 34778800
Significance: These data provide evidence that growth of the malignant clone in WM is preceded by expansion of extrafollicular B cells, myeloid inflammation, and immune dysfunction in the preneoplastic phase....
4.
Joseph N, Gupta V, Wyman S, Graiser M, Kaufman J, Almaula D, et al.
Transplant Cell Ther
. 2021 Oct;
28(2):75.e1-75.e7.
PMID: 34626863
Although survival outcomes have improved dramatically over the last few decades in newly diagnosed myeloma patients, elderly patients have not yielded the same magnitude of benefit as evidenced by higher...
5.
Buske C, Tedeschi A, Trotman J, Garcia-Sanz R, MacDonald D, Leblond V, et al.
J Clin Oncol
. 2021 Oct;
40(1):52-62.
PMID: 34606378
Purpose: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. Methods: Patients had confirmed...
6.
Kelly K, Ailawadhi S, Siegel D, Heffner L, Somlo G, Jagannath S, et al.
Lancet Haematol
. 2021 Sep;
8(11):e794-e807.
PMID: 34529955
Background: Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138 and synergistically enhances the antitumor activity of lenalidomide in preclinical models of multiple myeloma. This phase 1/2a study...
7.
Gupta V, Barwick B, Matulis S, Shirasaki R, Jaye D, Keats J, et al.
Blood
. 2021 Mar;
137(26):3604-3615.
PMID: 33649772
Venetoclax is a highly potent, selective BCL2 inhibitor capable of inducing apoptosis in cells dependent on BCL2 for survival. Most myeloma is MCL1-dependent; however, a subset of myeloma enriched for...
8.
Maples K, Nooka A, Gupta V, Joseph N, Heffner L, Hofmeister C, et al.
Am J Hematol
. 2020 Dec;
96(3):E68-E71.
PMID: 33275813
No abstract available.
9.
Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, OConnor O, et al.
Blood
. 2020 Nov;
137(19):2634-2645.
PMID: 33211842
The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains poor, with a need for alternatives to current salvage therapies. Loncastuximab tesirine (ADCT-402) is an antibody-drug...
10.
Jillella A, Arellano M, Gaddh M, Langston A, Heffner L, Winton E, et al.
JCO Oncol Pract
. 2020 Oct;
17(4):e497-e505.
PMID: 33125295
Purpose: Acute promyelocytic leukemia (APL) is a curable leukemia with > 90% survival in clinical trials. Population-based studies from Sweden and US SEER data have shown long-term survival rates of...